MediciNova Inc
MNOV
Company Profile
Business description
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.
Contact
4275 Executive Square
Suite 300
La JollaCA92037
USAT: +1 858 373-1500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
6
Stocks News & Analysis
stocks
WiseTech result disappoints, but the future looks bright
Markets appear underwhelmed by recent sales growth, however, our kingmaker thesis is intact.
stocks
WOW earnings: Woolworths losing market share, but will catch up to Coles
Woolworths have had a soft start to a challenging year, but Morningstar analyst believes it will eventually catch up to its main competitor.
stocks
Chart of the Week: Largest share price falls during earnings
Opportunities arise when the market overreacts, and good quality companies are mispriced.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,241.10 | 0.50 | -0.01% |
| CAC 40 | 7,762.60 | 18.67 | 0.24% |
| DAX 40 | 24,039.92 | 6.29 | -0.03% |
| Dow JONES (US) | 45,573.14 | 7.91 | 0.02% |
| FTSE 100 | 9,216.82 | 38.68 | -0.42% |
| HKSE | 24,998.82 | 202.94 | -0.81% |
| NASDAQ | 21,700.56 | 110.42 | 0.51% |
| Nikkei 225 | 42,828.79 | 308.52 | 0.73% |
| NZX 50 Index | 12,903.08 | 41.24 | 0.32% |
| S&P 500 | 6,495.76 | 14.36 | 0.22% |
| S&P/ASX 200 | 8,980.00 | 9.50 | 0.11% |
| SSE Composite Index | 3,843.60 | 43.25 | 1.14% |